UAB Diabetes Research Center recruiting for national study

diabetes 2UAB investigators are studying the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treating type 2 diabetes. Recruitment of volunteers for the project, called the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study, begins in June.

Doctors may add one of several other drugs to lower glucose, blood sugar, if metformin is not enough to manage type 2 diabetes in a person. While short-term studies have shown the efficacy of different drugs when used with metformin, there have been no long-term studies to determine which combination works best and has the fewest side effects.

“It is estimated that nearly 1 in 3 children, and actually 1 in 2 minority children, born after the year 2000 will develop type 2 diabetes,” said W. Timothy Garvey, M.D., professor and chair of the Department of Nutrition Sciences and co-primary investigator for the GRADE study at UAB. “Type 2 diabetes progresses gradually, and this study will help us understand how different combinations of medicine affect the disease and the people who are taking those medications over time.”

The UAB Diabetes Research Center (DRC), directed by Garvey, will host the study. The DRC features researchers from the schools of Health Professions, Medicine and Public Health, among other units.

GRADE aims to enroll about 5,000 patients at UAB and 36 other sites. Researchers are seeking people diagnosed with type 2 diabetes within the last five years. Participants may be on metformin, but not on any other diabetes medication. During the study, all participants will take metformin, along with a second medication randomly assigned from among four classes of medications, all approved for use with metformin by the U.S. Food and Drug Administration.

Three of the classes of medications increase insulin levels. They are: sulfonylurea, which increases insulin levels directly; DPP-4 inhibitor, which indirectly increases insulin levels by increasing the effect of a naturally occurring intestinal hormone; and GLP-1 agonist, which increases the amount of insulin released in response to nutrients. The fourth type of medication is a long-acting insulin.

The study will compare drug effects on glucose levels, adverse effects, diabetes complications and quality of life over an average of nearly five years.

Participants will have their diabetes medication managed free of charge through the study, including at least four medical visits per year, but will receive other health care through their own service provider. Those interested should contact Dana Golson by email, ccnrn@uab.edu or by phone, 205-996-4015.

“What separates this study from others is that we will compare, over a long period of time, the most commonly used type 2 diabetes drugs head-to-head,” said Andrea L. Cherrington, UAB co-primary investigator for the GRADE study at UAB and scientist in the DRC. “This study will help physicians administer personalized treatment, and ultimately provide better results for type 2 diabetes patients’ long-term care.”

Participants will have their diabetes medication managed free of charge through the study, including at least four medical visits per year, but will receive other health care through their own service provider. Those interested should contact Dana Golson by email, ccnrn@uab.edu or by phone, 205-996-4015.

David M. Nathan, M.D., of Massachusetts General Hospital, Boston and John Lachin, Sc.D., of The George Washington University, Washington, D.C., are co-principal investigators. Barbara Linder, M.D., Ph.D., of the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, is the project officer for GRADE.

GRADE (ClinicalTrials.gov number: NCT01794143) is supported under NIH grant U01DK098246. Additional support in the form of donation of supplies comes from the National Diabetes Education Program, Sanofi-Aventis, Bristol-Myers Squibb, Novo Nordisk, Merck, BD Medical and Roche Diagnostics.

Research & Scholarship

  • Graduate training to improve special education services gets a boost
    A $1.25 million grant from the U.S. Department of Education will fund scholarships, provide research opportunities and support collaboration between UAB's schools of Education and Health Professions to improve education services for young children with disabilities. Professor Jennifer Kilgo, Ed.D., who directs Project TransTeam, expects to train 70 scholars in five years.
    posted 6 days ago 105 views
  • Men and women process chronic pain differently
    Robert Sorge, Ph.D., assistant professor of psychology, is lead author of a paper published in Nature Neuroscience online that disputes the assumption that a common pain circuit exists in both sexes. New research shows males and females may use very different biological systems to process pain; the key difference appears to be in the immune system and under control of testosterone.
    posted 29 days ago 348 views
  • Will your self-driving car be programmed to kill you?
    The computer brains inside autonomous vehicles will be fast enough to make life-or-death decisions. But should they? A member of UAB’s national championship-winning Bioethics Bowl team — and the team’s coach, a renowned bioethicist — weigh in on a thorny problem of the dawning robot age.
    posted a while back 558 views
  • “Extra costs of extra weight for older adults”


    UAB research, clinical services featured in PBS story that examines the high and rising costs of health care for obese adults as they age.
    posted a while back 916 views
  • Smartphones are learning new tricks
    sensomatic main imageYou may think your phone can already do everything, but UAB cybersecurity researchers are adapting accelerometers, GPS chips, gyroscopes and other sensors to make phones that can read your mood, eliminate passwords, protect your bank account and more.
    posted a while back 834 views
  • Renowned expert named inaugural director of UAB Informatics Institute
    James J. Cimino, M.D., will lead UAB's new Informatics Institute, which was established in June 2014. Cimino, who previously was the chief of the Laboratory for Informatics Development at the NIH Clinical Center and a senior scientist at the National Library of Medicine, is a national leader in the field of biomedical informatics and co-editor of the most influential textbook on the subject.
    posted a while back 1038 views
  • Research enters data-driven era
    During the past few years, technological innovations have opened up an entirely new way to approach scientific questions. Data-driven research starts with massive information sets — the genomic profiles of thousands of patients, for example, or millions of spam emails — and then searches for emerging patterns in that data. In the latest issue of the U.S. Chamber of Commerce’s "Business Horizon Quarterly", UAB President Ray Watts, M.D., explains the way data-driven research at UAB is being applied to find novel treatments for disease, create new products and businesses and train the next generation of innovation-savvy students.
    posted a while back 1175 views
  • Fulbright scholar here to improve health care in Ukraine

    Iryna Mazhak, Ph.D., a Fulbright Visiting Scholar from Ukraine, is developing a medical sociology course and textbook materials during her nine months at UAB. No such course or textbook exists in her homeland, she says. 

    posted a while back 2936 views
  • How safe are you on the Internet?
    Participate in a brief, large-scale survey of Internet users that will help UAB researchers design strong authentication systems for securing information privacy.
    posted a while back 2500 views